Eli Lilly & Co.

Eli Lilly and Company is engaged in discovering, developing, manufacturing, and marketing products in two business segments: human pharmaceutical products; and animal health products. The company's human pharmaceutical products include: cardiovascular, endocrinology, immunology, neuroscience and oncology products. The company's animal health products are comprised of products for animals, among others, which include Clynav?, a vaccine to control pancreas disease in salmon; Coban?, Maxiban?, and Monteban?, anticoccidial agents for use in poultry; as well as products for companion animals, which include Comfortis?, a chewable tablet that kills fleas and prevents flea infestations on dogs.
  • TickerLLY
  • ISINUS5324571083
  • ExchangeNew York Stock Exchange
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

Analysts

ValuEngine Rating and Forecast Report for LLY

ValuEngine Rating and Forecast Report for LLY

Sel Hardy

Eli Lilly and Company

Sel Hardy

Eli Lilly and Company

ValuEngine Rating and Forecast Report for LLY

ValuEngine Rating and Forecast Report for LLY

Sel Hardy

Eli Lilly and Company

Marnik Hinnekens

TP ICAP - Europe - Morning CreditUpdate 24/10/2019 - Intrum, Ford - FR

Intrum (Achat) - 9M-19 : EBIT de SEK4,2 mds (€391m, +41,1%) Ford (Achat) : Abaisse ses perspectives pour 2019 Scor (Achat) - 9M-19 : Primes brutes de €12,1 mds (+3,2% à tcc) SEB (Achat) - 9M-19 : Résultat d’exploitation de SEK17,8 mds (€1,7 md, +4,8%) Constellium (Achat) : Revoit à la baisse ses objectifs 2019 Edenred (Achat) : Vise une croissance organique d’EBITDA >10% jusqu’à 2022 Europcar (Vente vs Achat) : Abaisse ses perspectives pour 2019 Schmolz + Bickenbach : Prévoit une augmentation de capital de CHF189m à CHF350m ...

Sel Hardy

Eli Lilly and Company

Sel Hardy

Eli Lilly and Company

Sel Hardy

Eli Lilly and Company

Sel Hardy

Eli Lilly and Company

Sel Hardy

Eli Lilly and Company

Eli Lilly & Co: 2 directors gave away/sold

Two Directors at Eli Lilly & Co gave away/sold 36,184 shares at between 0.000USD and 120.000USD. The significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under lis...

ValuEngine Rating and Forecast Report for LLY

ValuEngine Rating and Forecast Report for LLY

ValuEngine Rating and Forecast Report for LLY

ValuEngine Rating and Forecast Report for LLY

Sel Hardy

Eli Lilly and Company

ValuEngine Rating and Forecast Report for LLY

ValuEngine Rating and Forecast Report for LLY

ValuEngine Rating and Forecast Report for LLY

ValuEngine Rating and Forecast Report for LLY

The Bull Is Dead, Long Live The Bull - (GMR Weekly Notes - 2019 Outlooks - 2 Jan 2019)

Markets: Stocks: Pfizer (PFE); Eli Lilly (LLY); AbbVie (ABBV); Nexstar Media (NXST); Amazon (AMZN); Alibaba (BABA); JD.com (JD); Triton International (TRTN); Healthcare Sector ETF (XLV) Forex: EURGBP; Dollar Index (DXY); GBPJPY Rates: 2s/10s; 5s/30s; EDZ9

Slick and Hazardous: Will Fed Limit The Damage? (GMR Weekly Notes - 17 Dec 2018)

Markets This Week: Stocks: Financials ETF (XLF); Eli Lilly (LLY): Oracle (ORCL); Fedex (FDX); Micron (MU); Cree (CREE) Forex: GBPJPY; NZDUSD; USDZAR; USDCNY Rates: EDZ9; 5s/30s

Dominic Rose ...
  • Naresh Chouhan

Revenue Downgrade Cycle Almost Over

Persistent revenue downgrades have led to investor concern around future analyst forecasts, particularly for new drugs. Our analysis shows that the causes of the sector revenue downgrades have been largely driven by Primary Care launches in the US. More importantly, we show that the downside risk to future new product forecasts has fallen materially. We argue that if forecasts are now more accurate, the recent Pharma sell-off creates a good entry point.

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

Key Points: • A number of Consumer Cyclical names continue to reflect leadership. (ex. SBUX, RRGB, MCD, PZZA, and ROST.) • The Financial Sector has a number of attractive names developing major bases and staging RS reversals. (ex. SIVB, STT, AXP, SPGI, CME, GS, and JEF) • The Technology Sector has a number of technically attractive constituents. (ex. AMD, OLED, MPWR, CRUS, BR, FIS, VRSN, SAIC, LDOS, AAOI, BELFB, FARO, STX, and AAPL) .

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

Key Points: • A number of Consumer Cyclical names continue to reflect leadership. (ex. SBUX, RRGB, MCD, PZZA, and ROST.) • The Financial Sector has a number of attractive names developing major bases and staging RS reversals. (ex. SIVB, STT, AXP, SPGI, CME, GS, and JEF) • The Technology Sector has a number of technically attractive constituents. (ex. AMD, OLED, MPWR, CRUS, BR, FIS, VRSN, SAIC, LDOS, AAOI, BELFB, FARO, STX, and AAPL) .

Dave Nicoski ...
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

Dave Nicoski ...
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch